用多替阿巴拉米片需要注意什么事项呢？

It is an innovative drug for AIDS treatment by ViiV Healthcare, a joint venture company of GlaxoSmithKline (GSK). It is currently the only three-in-one compound drug containing dolutegravir (DTG). It has the characteristics of good tolerance, high resistance barrier and few drug interactions. One tablet per day can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and significantly improving their quality of life. On January 22, 2018, dolutegravir tablets were launched in China for the treatment of human immunodeficiency virus (HIV) infection. HIV-infected patients, regardless of their race, should be screened for HLA-B5701 alleles before starting treatment with abacavir-containing products. If the patient is known to carry the HLA-B5701 allele, he should not take products containing abacavir. Today, let’s learn about what you need to pay attention to when using Duotie Abalamid Tablets?

1Myocardial infarction

Observational studies have demonstrated an association between myocardial infarction and abacavir use. The patients participating in the study were mainly those who had received antiretroviral therapy. Clinical trial data show a limited number of myocardial infarctions and a small increase in risk cannot be ruled out. Overall, there are some inconsistencies between observational cohort data and randomized trial data, so a causal relationship between abacavir treatment and the risk of myocardial infarction cannot be confirmed or denied. To date, there is no precise biological mechanism to explain the possible increased risk. Steps should be taken to minimize all modifiable risk factors (e.g. smoking, hypertension, hyperlipidemia) while using dolutea.

2Osteonecrosis

Although the etiology is thought to be multifactorial (including use of corticosteroids, bisphosphonates, alcohol consumption, severe immunosuppression, and high body mass index), cases of osteonecrosis have been reported, particularly in patients with advanced HIV disease and/or long-term exposure to CART. Patients should be advised to seek medical attention if they experience joint pain, joint stiffness, or difficulty moving. 

3 opportunistic infections

Patients should be informed that dolutea or any other antiretroviral treatment does not cure HIV infection and that they may still develop opportunistic infections and other complications of HIV infection. Therefore, patients should be under close clinical observation by physicians experienced in treating HIV-related diseases.

  4 drug resistance

Because the recommended dose of dolutegravir in patients who are resistant to integrase inhibitors is 50 mg twice daily, dolutegravir is not recommended for use in patients who are resistant to integrase inhibitors.

The above is the content of the precautions, I hope it can help you!